Commercial Models Shifting As Pharma Mulls Digital-First Launches
Pharma is assessing digital-first launch strategies amid COVID-19 while a resizing of sales forces and the emergence of "digital orchestrators" may also be in store, the co-founder of healthcare solutions provider Indegene tells Scrip.
You may also be interested in...
Senior executives from Amgen and Sun Pharma discuss strategies to get brand launches right amid changing market dynamics. Over 40% of drug launches are currently estimated to fall short of their two-year targets.
Data is the new gold and Timmo Rousku Andersen, Boehringer Ingelheim’s corporate senior vice-president, head of global regions, outlines in an interview the German group's efforts to shape go-to-market models driven by data and insights. He also touches on digital therapeutics and how the firm’s R&D engine is pursuing deeper insights into interconnected disorders.
metaMe Health CEO and ex-Takeda executive Tim Rudolphi and partner firm Indegene’s senior vice president Marut Setia discuss with Scrip plans for the FDA-authorized, gut-directed hypnotherapy Regulora, including an openness to outcomes-based pricing and the wider go-to-market strategy.